CXCL13 as a Prognostic Biomarker and Modulator of the Tumor Microenvironment in Colorectal Cancer
Journal of Digestive Diseases · 2025
DOI: 10.1111/1751-2980.70001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Digestive Diseases, 2025. Verfasst von Fang Fang Guo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. Hauptthemen laut MEDLINE: Chemokine CXCL13, Tumor Microenvironment, Colorectal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Sichuan Province Science and Technology Support Program.
Abstract (Originalsprache)
Objectives
Immunotherapy yields limited results in patients with colorectal cancer (CRC), emphasizing the need for a deeper understanding of the immune landscape within the tumor microenvironment. Although the C‐X‐C motif chemokine ligand 13 (CXCL13) recruits B cells and promotes tertiary lymphoid structure (TLS) formation, its immune function and prognostic value in CRC remain unclear. This study investigated the impact of CXCL13 on patient outcomes and CRC immune landscape.
Methods
Four independent cohorts were recruited in this study. The Cancer Genome Atlas Program (TCGA) cohort evaluated survival differences as well as immune contexture associated with CXCL13 expression in CRC. Immunohistochemistry (IHC) in the Renji Hospital (RJ) cohort was used to validate CXCL13 and CD8 levels, while multiplex IHC assessed their spatial correlation. Two single‐cell RNA sequencing (scRNA‐seq) cohorts were used for evaluating the potential roles of CXCL13 and CXCL13 + CD8 + T cells in the immune context of CRC.
Results
Our study revealed a positive correlation between CXCL13 expression and improved survival among CRC patients. Elevated CXCL13 levels and CXCL13 + CD8 + T cells were linked to a favorable immune context that impeded tumor growth in CRC. Moreover, CXCL13 expression was more prevalent in microsatellite instability‐high (MSI‐H)/mismatch repair‐deficient (MMRd) tumors, demonstrating its potential role in enhancing the response to anti‐programmed death‐1 ligand (PD‐L1) treatment.
Conclusions
CXCL13 plays a critical role in shaping a favorable immune tumor microenvironment in CRC. Further research should elucidate how CXCL13 modulates CD8 + T cell function to improve antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China.
- State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Shanghai Cancer Institute, Shanghai Institute of…
- Department of General Surgery, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children's Health, Hangzhou, Zhejiang Province, China.
- Shanghai KR Pharmtech, Inc., Ltd., Shanghai, China.
- Department of Gastrointestinal Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Department of Gastroenterology, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan Province, China.
ORCID-Profile: Xiao Qiang Zhu
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Sichuan Province Science and Technology Support Program
- Sichuan Provincial Science and Technology Support Program
Zitieren
APA
Guo, F. F., Yan, Y. Q., Chen, W. W., Cheng, Y., Zhang, R., Shen, C. Q., Cui, Y., Peng, Y. S., Chen, H. Y., Ji, L. H., Xuan, B. Q., & Zhu, X. Q. (2025). CXCL13 as a Prognostic Biomarker and Modulator of the Tumor Microenvironment in Colorectal Cancer. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.70001
Vancouver
Guo FF, Yan YQ, Chen WW, Cheng Y, Zhang R, Shen CQ, et al. CXCL13 as a Prognostic Biomarker and Modulator of the Tumor Microenvironment in Colorectal Cancer. Journal of Digestive Diseases. 2025. doi:10.1111/1751-2980.70001
BibTeX
@article{Guo2025,
author = {Guo, Fang Fang and Yan, Yu Qing and Chen, Wei Wei and Cheng, Yao and Zhang, Rui and Shen, Chao Qin and Cui, Yun and Peng, Yan Shen and Chen, Hao Yan and Ji, Lin Hua and Xuan, Bao Qin and Zhu, Xiao Qiang},
title = {CXCL13 as a Prognostic Biomarker and Modulator of the Tumor Microenvironment in Colorectal Cancer},
journal = {Journal of Digestive Diseases},
year = {2025},
doi = {10.1111/1751-2980.70001}
}
EUVIMED